Gilead Sciences Inc (NASDAQ:GILD)

64.92
Delayed Data
As of Mar 21
 +0.32 / +0.50%
Today’s Change
60.32
Today|||52-Week Range
79.61
+3.79%
Year-to-Date
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
Mar 19 / Zacks.com - Paid Partner Content
Is iShares Nasdaq Biotechnology Index Fund a Buy?
Mar 11 / MotleyFool.com - Paid Partner Content
Better Buy: Amgen vs. Gilead Sciences
Mar 17 / MotleyFool.com - Paid Partner Content
3 Top Biotech Stocks to Buy in March
Mar 09 / MotleyFool.com - Paid Partner Content
Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up
Mar 14 / Zacks.com - Paid Partner Content
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
Mar 08 / Zacks.com - Paid Partner Content
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
Mar 13 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close64.60
Today’s open64.14
Day’s range63.00 - 65.02
Volume9,069,470
Average volume (3 months)7,754,409
Market cap$83.3B
Data as of 4:00pm ET, 03/21/2019

Growth & Valuation

Earnings growth (last year)+4.62%
Earnings growth (this year)-0.52%
Earnings growth (next 5 years)+1.08%
Revenue growth (last year)-15.00%
P/E ratio15.6
Price/Sales3.68
Price/Book3.91

Competitors

 Today’s
change
Today’s
% change
BIIBBiogen-93.71-29.23%
AMGNAmgen+0.77+0.40%
ILMNIllumina Inc+3.91+1.24%
EXASExact Sciences Corp+1.54+1.70%
Data as of 4:00pm ET, 03/21/2019

Financials

Next reporting dateMay 2, 2019
EPS forecast (this quarter)$1.62
Annual revenue (last year)$22.2B
Annual profit (last year)$5.5B
Net profit margin24.56%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Daniel O'Day
CFO, Principal Accounting Officer &
Executive VP
Robin L. Washington
Corporate headquarters
Foster City, California

Forecasts